BioStock: Fluicell’s CRO services diversify revenue opportunities

Fluicell’s main objective is to empower researchers in the healthcare sector to push the bounds of science. The life science company manages this not only by offering a range of innovative single-cell research tools, but also by providing CRO services to researchers aiming for new drug discoveries. The activities, along with academic partnerships, are strong drivers of Fluicell’s growth.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.

About Us

Based in Gothenburg Sweden, Fluicell is a company that has commercialized a product portfolio to study single cells, primarily in the field of drug development. Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail. As a further development of Fluicell's existing product portfolio, the company has developed a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar®. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled.


Documents & Links

Quick facts

BioStock: Fluicell’s CRO services diversify revenue opportunities
Tweet this